rc48-adc
B-NHL
Ruijin Hospitalantibody_drug_conjugatePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the B-NHL cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tislelizumab Ruijin Hospital | Phase 2 | CCC |
Pyrotinib Ruijin Hospital | Phase 2 | CCC |
ly007 Ruijin Hospital | Phase 1 | CC |
Same molecule, other indications
rc48-adc is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →